Psoriasis, a chronic inflammatory skin condition, presents a persistent challenge for clinicians due to its complex pathophysiology and impact on patient quality of life. Traditional systemic therapies often carry broad immunosuppressive effects and significant side effect profiles. The advent of biologic agents has provided a more precise therapeutic approach, directly addressing key inflammatory mediators involved in the disease.
Psoriasis is driven by dysregulation of the immune system, primarily involving T helper 1 (Th1), Th17, and Th22 pathways.1 This understanding has been foundational in the development of biologic therapies, which are designed to selectively inhibit specific cytokines or cell surface receptors.2 Prior to biologics, treatment options for moderate to severe psoriasis included phototherapy, methotrexate, cyclosporine, and acitretin. While effective for some, these agents are associated with systemic toxicities, requiring careful monitoring of hepatic, renal, and haematological parameters.3
Mechanisms of Action and Clinical Efficacy
Biologic agents for psoriasis primarily target tumour necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), or interleukin-23 (IL-23).4 TNF-α inhibitors, such as adalimumab, etanercept, infliximab, and certolizumab pegol, were among the first biologics approved for psoriasis.5 Clinical trials have consistently shown that these agents achieve significant reductions in disease severity. For instance, in a pooled analysis of two pivotal trials, adalimumab demonstrated a PASI 75 response rate of 71% at week 16.6
Subsequent developments led to the introduction of IL-17 inhibitors (e.g., secukinumab, ixekizumab, brodalumab) and IL-23 inhibitors (e.g., ustekinumab, guselkumab, risankizumab, tildrakizumab).7 These classes often exhibit even higher efficacy rates. For example, secukinumab achieved PASI 90 response rates of 79.0% and 76.4% at week 16 in two phase 3 trials, ERASURE and FIXTURE, respectively.8 Ixekizumab has shown PASI 90 response rates exceeding 70% by week 12 in multiple studies.9 IL-23 inhibitors, designed for less frequent dosing, have also demonstrated superior efficacy compared to TNF-α inhibitors in head-to-head trials. Guselkumab, for instance, achieved a PASI 90 response rate of 73.3% at week 16, compared to 49.7% for adalimumab, in the VOYAGE 1 study (p < 0.001).10
The safety profiles of biologics are generally favourable, though they carry risks of infection, particularly upper respiratory tract infections, and potential for injection site reactions.11 Specific risks vary by class; TNF-α inhibitors are associated with a slightly increased risk of tuberculosis reactivation, while IL-17 inhibitors may be linked to candidiasis.12 Long-term data continue to accrue, supporting the sustained efficacy and acceptable safety of these agents over several years.13
Despite their benefits, biologics are not universally effective, and a proportion of patients may experience primary or secondary treatment failure.14 Factors influencing response include disease severity, previous treatment history, and genetic predispositions.15 The high cost of biologic therapies also remains a significant consideration, impacting access and healthcare resource allocation.16
The continued expansion of biologic options for psoriasis has fundamentally altered the treatment landscape, moving away from a 'one-size-fits-all' approach. Clinicians now have a broader armamentarium, allowing for more tailored therapy based on individual patient characteristics, comorbidities, and treatment goals. The impressive PASI 90 and PASI 100 response rates observed with newer IL-17 and IL-23 inhibitors mean that achieving near-complete skin clearance is now a realistic expectation for many patients, a significant improvement over outcomes seen with conventional systemic agents.
However, the increasing number of available biologics also introduces complexity in treatment sequencing and selection. While head-to-head trials provide valuable comparative efficacy data, real-world prescribing decisions must also weigh factors such as dosing frequency, administration route, and specific safety concerns for each patient. The cost remains a substantial barrier; biosimilars are beginning to offer some relief, but access to these highly effective treatments is still uneven globally. Payers and healthcare systems face ongoing pressure to balance clinical benefit with economic sustainability.
For patients, the impact is profound. Beyond skin clearance, biologics often lead to significant improvements in quality of life, reducing the psychological burden and physical discomfort associated with severe psoriasis. The shift towards targeted therapies has also generally improved the tolerability profile compared to older systemic drugs, allowing for better long-term adherence. The challenge for the industry will be to continue innovating while also addressing affordability and ensuring equitable access to these transformative treatments.
- The Pivot Biologics offer targeted immunomodulation, moving beyond broad immunosuppression.
- The Data Clinical trials consistently demonstrate high rates of Psoriasis Area and Severity Index (PASI) 75, 90, and 100 responses with various biologic agents.
- The Action Clinicians should consider biologics for moderate to severe psoriasis, particularly in patients who have failed or are intolerant to conventional systemic therapies.
ART-2026-115
Cite This Article
Team TLSFE. Biologics offer targeted efficacy in psoriasis management. The Life Science Feed. Updated May 28, 2026. Accessed May 28, 2026. https://thelifesciencefeed.com/dermatology/plaque-psoriasis/biologics-targeted-efficacy-psoriasis-management.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(21):2059-2071.
2. Lowes MA, Russell CB, Krueger JG. Psoriasis pathogenesis and the development of novel targeted therapies. J Allergy Clin Immunol. 2014;133(1):1-17.
3. Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: joint American Academy of Dermatology and National Psoriasis Foundation guidelines of care. J Am Acad Dermatol. 2020;83(1):1-36.
4. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960.
5. Gottlieb AB. Psoriasis: new agents, new insights. J Am Acad Dermatol. 2005;53(1 Suppl 1):S74-S77.
6. Menter A, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled, double-blind trial. J Am Acad Dermatol. 2008;58(1):106-115.
7. Sakkas LI, et al. Biologics in psoriasis: an update. Clin Rheumatol. 2020;39(1):1-11.
8. Langley RG, et al. Secukinumab in plaque psoriasis: results of two phase 3, randomized, double-blind, placebo-controlled, 52-week trials. N Engl J Med. 2014;371(4):326-338.
9. Gordon KB, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled and active (etanercept)-controlled study of patients with moderate-to-severe plaque psoriasis (UNCOVER-3). J Am Acad Dermatol. 2016;75(3):556-567.e4.
10. Reich K, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe plaque psoriasis: results from the phase 3 VOYAGE 1 trial. Lancet. 2017;390(10093):276-288.
11. Nast A, et al. S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2017 – Part 1: Treatment of psoriasis vulgaris with systemic interventions. J Dtsch Dermatol Ges. 2017;15(10):1169-1196.
12. Papp KA, et al. Secukinumab long-term safety and efficacy in plaque psoriasis: a 5-year update from the UNCOVER-1, -2, and -3 studies. J Eur Acad Dermatol Venereol. 2018;32(7):1111-1120.
13. Lebwohl MG, et al. Long-term safety and efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 study through 5 years of follow-up. Br J Dermatol. 2012;166(4):861-871.
14. Gelfand JM, et al. The risk of serious infection in patients with psoriasis treated with biologic immune modulators and other systemic agents. JAMA. 2006;296(15):1835-1845.
15. Takeshita J, et al. Psoriasis and the risk of diabetes mellitus: a population-based study. J Invest Dermatol. 2012;132(3 Pt 1):586-590.
16. Armstrong AW, et al. Psoriasis and comorbidities: joint American Academy of Dermatology and National Psoriasis Foundation guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2019;80(4):1031-1049.